What is the maximum recommended dose of sumatriptan nasal spray for an adult?

Maximum Dose of Sumatriptan Nasal Spray

The maximum recommended dose of sumatriptan nasal spray is 40 mg per 24-hour period, administered as 5-10 mg (one to two sprays) in one nostril, with the dose repeated after 2 hours if needed. 1

Dosing Algorithm

Initial Dose

• Start with 5-10 mg (one to two sprays) in one nostril 1
• Administer when headache pain is moderate to severe 1

Repeat Dosing

• If headache returns or there is partial response, repeat the dose after 2 hours 1
• Do not exceed 40 mg total in any 24-hour period 1

Dose Selection Considerations

• The 20 mg dose has demonstrated the highest efficacy rates across multiple parameters, with 60-63% of patients achieving headache relief at 2 hours compared to 29-35% with placebo 2
• The 10 mg dose shows intermediate efficacy (43-54% relief at 2 hours) 2
• The 5 mg dose is less consistently effective 2

Important Clinical Caveats

Contraindications to All Doses

• Do not use within 24 hours of another triptan or ergotamine-containing medication 1
• Contraindicated in patients with coronary artery disease, cerebrovascular disease, uncontrolled hypertension, hemiplegic or basilar migraine 1
• Contraindicated with MAO inhibitor use 1

Timing Between Routes

• If a patient has already used subcutaneous sumatriptan (maximum 12 mg/24 hours), additional nasal spray doses must respect the 2-hour interval and should not be used if cardiovascular risk is elevated 3

Frequency Limitations

• The safety of treating more than 4 headaches in a 30-day period has not been established 3
• This is critical to prevent medication overuse headache

Onset of Action

• Intranasal sumatriptan provides relief as early as 15 minutes postdose with the 20 mg formulation 2
• This is faster than oral tablets (2-2.5 hours) but slower than subcutaneous injection (15 minutes to peak concentration) 1, 3

Common Adverse Effects

• Taste disturbance (bad, bitter, or unpleasant taste) is the most common adverse event, reported by up to 68% of patients 4, 2, 5
• Other adverse events include nausea, warmth, vertigo, and chest pressure 1
• The adverse event profile is generally more favorable than subcutaneous administration but includes the unique taste disturbance 2